High-mobility group AT-hook protein 2 expression and its prognostic significance in MGMT methylated and unmethylated glioblastoma

  • Authors:
    • Frank P. Schwarm
    • Florian Uhle
    • Anne Schänzer
    • Till Acker
    • Marco Stein
    • Marcus H.T. Reinges
    • Cornelia Weischer
    • Marcus A. Weigand
    • Eberhard Uhl
    • Malgorzata A. Kolodziej
  • View Affiliations

  • Published online on: February 17, 2016     https://doi.org/10.3892/ijo.2016.3397
  • Pages: 1485-1492
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

High-mobility group AT-hook protein 2 (HMGA 2) is a transcription factor associated with malignancy and poor prognosis in a variety of human cancers. We correlated HMGA 2 expression with clinical parameters, survival, and O-6-methylguanine-DNA methyltransferase methylation status (MGMT) in glioblastoma patients. HMGA 2 expression was determined by performing quantitative real-time polymerase chain reaction (qPCR) and immunohistochemistry (IHC) in 44 glioblastoma patients and 5 non-tumorous brain specimens as controls. Gene expression levels of MGMT methylated vs. unmethylated patients, and gene expression levels between patient groups, both for qPCR and IHC data were compared using the Mann-Whitney U test. The relationship between HMGA 2 expression, progression-free survival and overall survival was analyzed using the Kaplan-Meier method and the log-rank test. P-values of <0.05 were considered statistically significant throughout the analyses. The mean age of patients at diagnosis was 57.4±15.7 years, and the median survival was 16 months (SE 2.8; 95% CI, 10.6-21.4). HMGA 2 gene expression was significantly higher in glioblastoma compared to normal brain tissue on qPCR (mean, 0.35; SD, 0.27 vs. 0.03, SD, 0.05) and IHC levels (IRS mean, 17.21; SD, 7.43 vs. 3.20; SD, 1.68) (p=0.001). Survival analysis revealed that HMGA 2 overexpression was associated with a shorter progression-free and overall survival time in patients with methylation (n=24). The present study shows a tendency that HMGA 2 overexpression correlates with a poor prognosis of glioblastoma patients independent of MGMT methylation status. The results suggest that HMGA 2 could play an important role in the treatment of glioblastoma and could have a function in prognosis of this type of cancer.
View Figures
View References

Related Articles

Journal Cover

April 2016
Volume 48 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Schwarm, F.P., Uhle, F., Schänzer, A., Acker, T., Stein, M., Reinges, M.H. ... Kolodziej, M.A. (2016). High-mobility group AT-hook protein 2 expression and its prognostic significance in MGMT methylated and unmethylated glioblastoma. International Journal of Oncology, 48, 1485-1492. https://doi.org/10.3892/ijo.2016.3397
MLA
Schwarm, F. P., Uhle, F., Schänzer, A., Acker, T., Stein, M., Reinges, M. H., Weischer, C., Weigand, M. A., Uhl, E., Kolodziej, M. A."High-mobility group AT-hook protein 2 expression and its prognostic significance in MGMT methylated and unmethylated glioblastoma". International Journal of Oncology 48.4 (2016): 1485-1492.
Chicago
Schwarm, F. P., Uhle, F., Schänzer, A., Acker, T., Stein, M., Reinges, M. H., Weischer, C., Weigand, M. A., Uhl, E., Kolodziej, M. A."High-mobility group AT-hook protein 2 expression and its prognostic significance in MGMT methylated and unmethylated glioblastoma". International Journal of Oncology 48, no. 4 (2016): 1485-1492. https://doi.org/10.3892/ijo.2016.3397